BioSpecifics Announces Positive XIAPEXÃ‚® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
LYNBROOK, N.Y., June 1, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that positive data for XIAPEX® (clostridial collagenase histolyticum for injection) were presented at the XVIth Annual Federation of European Societies for Surgery of the Hand (FESSH) Congress which took place in Oslo, Norway at the Oslo Congress Centre on May 26-28, 2011. Pfizer conducted a satellite symposium on XIAPEX treatment for Dupuytren's contracture.
"Pfizer had a strong presence at the FESSH Congress, including significant sponsorship of the conference, and indicates to us that they are very committed to a successful European launch for XIAPEX. In addition, the XIAPEX presentations were very well attended and attracted a considerable amount of interest from the surgeons that were present," reflected Thomas Wegman, President of BioSpecifics. "Data based on a statistical analysis of patients that had previously undergone surgery for Dupuytren's contracture and received successful subsequent treatment with XIAPEX are particularly important because they suggest that XIAPEX may be a very promising treatment option for patients who experience recurrence of symptoms after having surgery for Dupuytren's contracture."
Statistical analysis of data for 12 previous clinical trials conducted with XIAPEX were carried out for 422 patients that had previous hand surgery, and showed that there were no clinical or statistically meaningful differences in treatment outcome between hands that had undergone previous surgery for Dupuytren's contracture versus those that had not. Specifically, after XIAPEX treatment for metacarpophalangeal, or MP, joints in previously operated hands, the mean decrease in fixed flexion contracture was 75 +/- 2.8% while patients treated in hands that h